The two names sound like variants of the same thing, and the search volume splits roughly evenly between people typing them in either order. The difference is one component. GLOW is a three-compound blend. KLOW is the same three compounds plus KPV.
That single addition is the entire comparison, and it is worth understanding at the component level rather than treating the two as tiers of one product. This guide covers what is in each blend, what KPV brings mechanically, what each blend is examined for in published research, and how the two are supplied. Both blends are sold for laboratory and research use only, and no dosing values appear anywhere in this post.
What is in each blend
| Blend | Components | Component count | Sizes supplied by WWP |
|---|---|---|---|
| GLOW | BPC-157, TB-4 (thymosin beta-4 fragment, commonly listed as TB-500), GHK-Cu | 3 | 50mg, 70mg |
| KLOW | BPC-157, TB-4 (TB-500), GHK-Cu, KPV | 4 | 80mg |
WWP lists these as GLOW (BPC-157 / TB-4 / GHK-Cu) and KLOW (BPC-157 / TB-4 / GHK-Cu / KPV). The naming convention is not standardized across the industry. Both names are market conventions, not designations from any standards body, and component ratios differ between vendors. If you are comparing a KLOW listing from two suppliers, compare the stated component breakdown, not the name on the label.
Component by component
| Componente | Class and structure | What the published literature examines it for |
|---|---|---|
| BPC-157 | Synthetic pentadecapeptide, 15 amino acids, described by its originators as a partial sequence of a gastric-juice protein | VEGFR2 and nitric oxide pathway signaling, FAK-paxillin cell migration cascade, gastrointestinal and tendon fibroblast models |
| TB-4 / TB-500 | Acetylated 7-residue actin-binding motif (LKKTETQ) of thymosin beta-4, a 43-amino-acid actin-binding polypeptide | G-actin sequestration, cytoskeletal assembly, endothelial cell migration, cardiac and corneal wound models |
| GHK-Cu | Copper-binding tripeptide, glycyl-L-histidyl-L-lysine, complexed with copper(II); isolated from human plasma in 1973 by Pickart | Copper transport, collagen and glycosaminoglycan synthesis in fibroblast culture, MMP and TIMP expression, antioxidant enzyme literature |
| KPV | Tripeptide, lysine-proline-valine; corresponds to the C-terminal 11-13 residues of alpha-MSH | NF-κB and MAPK pathway attenuation in cell models, PepT1-mediated uptake in intestinal epithelial cells, inflammatory signaling assays |
The first two components are the pair covered in detail in BPC-157 vs TB-500. GHK-Cu is what turns that pair into GLOW. KPV is what turns GLOW into KLOW.
What GHK-Cu contributes
GHK-Cu is the component that pulls both blends into the dermal and connective-tissue literature. It is a three-amino-acid sequence that binds copper(II) with high affinity, first isolated by Loren Pickart in 1973 from a fraction of human plasma albumin.
Most of the published work on it sits in fibroblast culture. Studies examine collagen and glycosaminoglycan synthesis, expression of matrix metalloproteinases and their tissue inhibitors, and copper-dependent antioxidant enzyme activity. There is also a body of gene-expression profiling work reporting broad transcriptional changes in fibroblast lines exposed to the peptide.
The copper complex is also why these blends look different in the vial. GHK-Cu carries a blue tint in solution, which is a property of the copper coordination, not an indicator of purity or concentration. WWP also supplies GHK-Cu on its own in 50mg and 100mg vials for anyone running it as a single-component arm.
What the added KPV changes
KPV is a tripeptide: lysine, proline, valine. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone, positions 11-13.
The structural point that matters is what KPV lacks. Alpha-MSH contains the sequence region responsible for melanocortin receptor binding associated with pigmentation. KPV does not include that region. Published work describes it as retaining the anti-inflammatory signaling behavior attributed to the parent hormone in cell models without the pigmentation-associated activity.
Mechanistically, the KPV literature is dominated by inflammatory signaling rather than tissue architecture. Papers examine attenuation of NF-κB and MAPK pathway activation in cultured cells, and a well-cited 2008 paper describes PepT1-mediated uptake of the tripeptide in intestinal epithelial cells, which is why KPV appears in gut-model literature.
So the mechanical difference between the two blends is a category difference, not a strength difference. GLOW combines three components whose literatures center on vessel formation, cytoskeletal behavior, and matrix synthesis. KLOW adds a fourth whose literature centers on inflammatory pathway signaling. KLOW is not “stronger GLOW.” It is GLOW with a different class of component attached.
WWP supplies KPV separately in 5mg and 10mg vials for studies that want to isolate that variable.
Research applications examined for each
Neither list is a claim about outcomes. These describe the categories of study the component literature falls into.
GLOW components appear in research examining:
- Angiogenesis and endothelial migration assays
- Fibroblast collagen and glycosaminoglycan synthesis
- Extracellular matrix remodeling, including MMP and TIMP expression
- Dermal and corneal wound-model literature
- Cytoskeletal assembly and G-actin availability
- Copper-dependent antioxidant enzyme activity
KLOW components appear in all of the above, plus research examining:
- NF-κB pathway activation in cultured cell lines
- MAPK signaling attenuation
- Intestinal epithelial models and PepT1 transporter uptake
- Inflammatory cytokine expression profiling
The overlap is deliberate. A four-component blend inherits the study categories of all four components, which is also the methodological problem with blends generally: a result produced by a blend arm cannot be attributed to any one component. Blend arms answer whether a combination behaves differently from control. They do not answer which component did the work. Any study designed to answer that needs single-component arms alongside the blend.
Sizing and specifications
| GLOW | KLOW | |
|---|---|---|
| Components | BPC-157, TB-4, GHK-Cu | BPC-157, TB-4, GHK-Cu, KPV |
| Total peptide per vial | 50mg or 70mg | 80mg |
| Formato | Polvere liofilizzata | Polvere liofilizzata |
| Purezza | ≥99% | ≥99% |
| Pack size | 10 vials | 10 vials |
| Archiviazione | 2-8°C unopened, stable 12+ months | 2-8°C unopened, stable 12+ months |
| Utilizzo | Research purposes only, not for human use | Research purposes only, not for human use |
The milligram figures are total peptide content across all components in the vial, not per component. This is the number most worth checking when comparing listings between suppliers, because a 70mg three-component blend and an 80mg four-component blend do not contain the same amount of any individual compound. Two vendors can both sell an “80mg KLOW” with materially different component splits.
Common questions about KLOW and GLOW research
What is the difference between KLOW and GLOW?
Component count. GLOW contains BPC-157, TB-4 (thymosin beta-4 fragment, listed by most vendors as TB-500), and GHK-Cu. KLOW contains those same three plus KPV, a tripeptide fragment of alpha-MSH studied for inflammatory pathway signaling. Everything else about the two, including format, purity spec, and storage conditions, is the same.
What is the KLOW peptide blend?
KLOW is a four-component research blend supplied as a single lyophilized vial: BPC-157, thymosin beta-4 fragment, GHK-Cu, and KPV. The name is a market convention rather than a standardized designation, and component ratios are not consistent across suppliers. Anyone sourcing it for research should verify the component breakdown per vial rather than relying on the blend name.
What does the added KPV do at a mechanism level?
The published literature on KPV centers on inflammatory signaling in cell models, specifically attenuation of NF-κB and MAPK pathway activation, along with PepT1-mediated uptake in intestinal epithelial cells. That is a different mechanistic category from the other three components, whose literatures center on vessel formation, cytoskeletal dynamics, and matrix synthesis. Adding KPV widens the range of pathways represented in the vial rather than intensifying the existing ones.
Are the component ratios standardized between vendors?
No. There is no standards body defining what GLOW or KLOW means, and different suppliers use different splits at the same total milligram figure. Two vials labeled identically can contain meaningfully different amounts of each compound. This is the main reason to compare stated component breakdowns and independent test results rather than blend names.
Should a study use a blend or single compounds?
That depends on what the study is measuring. A blend arm can show whether a combination behaves differently from control, but it cannot attribute a result to any individual component. Studies designed to isolate component contribution need single-compound arms alongside the blend, which means ordering BPC-157, TB-4, GHK-Cu, and KPV separately. Blends are the more economical line item when component attribution is not the question.
Are these blends approved for human use?
No. Every component in both blends is an unapproved substance supplied for laboratory and research use only, not for human consumption, ingestion, injection, or therapeutic use. BPC-157 and thymosin beta-4 are also prohibited under anti-doping rules for competing athletes. We do not provide protocol design, dosing guidance, or administration parameters for any product.
Verifying what is in the vial
Blends are harder to verify than single compounds, which is exactly why the documentation matters more here. A certificate of analysis on a four-component blend should identify each component, not report a single aggregate purity figure with no breakdown.
Our COA library publishes third-party test results organized by product and batch. Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.
Where to find each
WWP manufactures and ships direct in 10-vial packs, with a 5-pack minimum per order across either shipping line. Products ship unlabeled because they move from production to the buyer without retail packaging in between.
- KLOW (BPC-157 / TB-4 / GHK-Cu / KPV) - 80mg
- GLOW (BPC-157 / TB-4 / GHK-Cu) - 50mg and 70mg
- BPC-157 - 5mg and 10mg
- KPV - 5mg and 10mg
For the mechanism-level breakdown of the two components both blends share, see BPC-157 vs TB-500.
All products sold by World Wide Peptides are for laboratory and research use only. They are not for human consumption, ingestion, injection, or therapeutic use.